FOR IMMEDIATE RELEASE

PlantForm, PharmaPraxis sign biopharmaceutical product development agreement

Companies target biosimilar and/or biobetter versions of six leading biologic drugs coming off patent protection in the next six years

GUELPH, Ont., Canada and RIO DE JANEIRO, Brazil, May 23, 2013—Canadian company PlantForm Corporation and Brazil-based PharmaPraxis have signed a collaboration and license agreement to develop, manufacture and commercialize biosimilar and/or biobetter versions of key biologic drugs using PlantForm’s patented plant expression system.

The companies will initially develop biosimilar and/or biobetter versions of six leading monoclonal antibody products that have combined total annual global sales of $31.5 billion and are scheduled to lose patent protection within the next six years.

“PharmaPraxis is an important strategic partner for us as we commercialize our plant-based manufacturing platform for biologic drugs,” said Dr. Don Stewart, PlantForm’s President and CEO. “We look forward to working together to bring highly valuable, lower-cost biopharmaceuticals to the Brazilian market and beyond.”

"Alternative routes of biopharmaceutical expression is a key element in PharmaPraxis' corporate strategy,” said PharmaPraxis CEO Eduardo Cruz. "We aim to bring innovative cutting edge technology to Brazil, and PlantForm's is certainly within that goal. We will bring valuable and less expensive biologic drugs to the Brazilian and Latin American markets."

PlantForm Corporation was established in 2008 to produce low-cost biologic drugs for cancer and other critical conditions. Biosimilar versions of three antibody drugs for cancer are currently in development, as are antibodies for the treatment of human immunodeficiency virus. PlantForm is also developing an enzyme to protect against nerve agent exposure under contract with the U.S. Defense Advanced Research Projects Agency. Projected revenue is more than $50 million by 2017.

PharmaPraxis is a biopharmaceutical technology platform corporation focused on manufacturing and commercializing biosimilar and innovator biologic drugs, pharmacogenomic and genetic kits, and alternative routes for biopharmaceutical expression. The company’s main target areas are genetic disorders, immune inflammatory disorders, cancer, individualized medicine and neglected diseases. PharmaPraxis is part of the Axis Biotec Brasil group of companies, which also includes Silvestre Labs, Cryopraxis and CellPraxis.

-30-
For more information, please contact:

Don Stewart
PlantForm President and CEO
don.stewart@plantformcorp.com
416-452-7242

Stacey Curry Gunn
PlantForm Director of Communications
stacey.curry.gunn@plantformcorp.com
519-827-1131

Eduardo Cruz
PharmaPraxis CEO
ce@axisbiotec.com.br
55 21 3035 69 50

Tatiana Lima
PharmaPraxis Technical Director
pharmapraxis@pharmapraxis.com.br
55 21 2142 7725